Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience

• Michael B. Bass ,

  * E-mail: mbass@amgen.com (MBB); mbass@amgen.com (SSC)

  Affiliation Molecular Sciences and Computational Biology, Amgen Inc., Thousand Oaks, CA, United States of America

  ⨯
• Bin Yao,

  Affiliation Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, United States of America

  ⨯
• Yong-Jiang Hei,

  Affiliation Oncology Development, Amgen Inc., Thousand Oaks, CA, United States of America

  ⨯
• Yining Ye,

  Affiliation Global Biostatistical Science, Amgen Inc. South San Francisco, San Francisco, CA, United States of America

  ⨯
• Gerard J. Davis,

  Affiliation Diagnostics Division Research and Development, Abbott Laboratories, Abbott Park, IL, United States of America

  ⨯
• Michael T. Davis,

  Affiliation Molecular Sciences and Computational Biology, Amgen Inc., Thousand Oaks, CA, United States of America

  ⨯
• Barbara A. Kaesdorf,

  Affiliation Diagnostics Division Research and Development, Abbott Laboratories, Abbott Park, IL, United States of America

  ⨯
• Sabrina S. Chan ,

  * E-mail: mbass@amgen.com (MBB); mbass@amgen.com (SSC)

  Affiliation Diagnostics Division Research and Development, Abbott Laboratories, Abbott Park, IL, United States of America

  ⨯
• Scott D. Patterson

  Affiliation Medical Sciences, Amgen Inc., Thousand Oaks, CA, United States of America

  ⨯